Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India

• Published in: Journal of clinical tuberculosis and other mycobacterial diseases 2024-05, Vol.35, p.100433-100433, Article 100433
• Main Authors: Mongia, Himani, Mamnoon, Fatima, Silsarma, Arunima, Mahajan, Raman, Dalal, Alpa, Galindo, Miriam Arago, Iyer, Aparna, Singh, Pramila, Mansoor, Homa, Das, Mrinalini, Morales, Mabel, Spencer, Hannah, Isaakidis, Petros
• Format: Article
• Language: English
• Subjects: Bedaquiline; Delamanid; Drug resistance; Extrapulmonary tuberculosis; India
• ISSN: 2405-5794; 2405-5794
• DOI: 10.1016/j.jctube.2024.100433

World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberculosis (DR-TB); however, data for patients with drug-resistant extrapulmonary tuberculosis (EPTB) is extremely limited. This study documents the treatment outcomes and adverse events associated with concurrent BDQ-DLM-based regimens in patients with drug-resistant EPTB at a Médecins Sans Frontières clinic in Mumbai, India. Retrospective cohort study based on routinely collected programmatic data. Individualised regimens were based on drug-susceptibility testing and previous drug exposure. Drug-resistant EPTB patients initiated on regimens containing concurrent BDQ and DLM from April 2016 to October 2019 were included.Patients who completed treatment were followed up at 12 months. Of 17 patients, median age was 23 years (IQR = 21–30 years) and 12/17 (71 %) were female. Pre-extensively drug-resistant tuberculosis and extensively drug-resistant TB was reported in 13/17 (76.4 %) and 2/17 (11.7 %) patients respectively. Microbiological reports were unavailable for two patients with central nervous system TB. Lymph node TB was the commonest form of EPTB in 9/17 (53 %) of patients. Median duration of treatment was 18.9 months. At least one grade three or four severe adverse event (SAE) was reported by 13/17 (76.4 %) patients. Thirteen (76.4 %) patients had favourable outcomes. None of the patients relapsed or died in the one-year period of post-treatment follow-up. Concurrent BDQ-DLM-based regimens in drug-resistant EPTB were effective and associated with manageable adverse events.